Teva Pharmaceutical (NYSE:TEVA) is scheduled to announce Q3 earnings results on Thursday, November 7th, before market open.
The consensus EPS Estimate is $0.59 (-13.2% Y/Y) and the consensus Revenue Estimate is $4.23B (-6.6% Y/Y).
Over the last 2 years, TEVA has beaten EPS estimates 75% of the time and has beaten revenue estimates 50% of the time.
Over the last 3 months, EPS estimates have seen 10 upward revisions and 5 downward. Revenue estimates have seen 6 upward revisions and 9 downward.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.